India
· Delayed Price · Currency is INR Piramal Pharma Statistics
Total Valuation
Piramal Pharma has a market cap or net worth of INR 326.00 billion. The enterprise value is 369.78 billion.
| Market Cap | 326.00B |
| Enterprise Value | 369.78B |
Important Dates
The last earnings date was Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | Jul 12, 2024 |
Share Statistics
Piramal Pharma has 1.33 billion shares outstanding. The number of shares has increased by 9.21% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.33B |
| Shares Change (YoY) | +9.21% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 0.20% |
| Owned by Institutions (%) | 26.13% |
| Float | 607.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 72.93 |
| PS Ratio | 3.72 |
| PB Ratio | 4.13 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 26.59, with an EV/FCF ratio of -1,191.31.
| EV / Earnings | 815.75 |
| EV / Sales | 4.25 |
| EV / EBITDA | 26.59 |
| EV / EBIT | 56.43 |
| EV / FCF | -1,191.31 |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 0.61.
| Current Ratio | 1.03 |
| Quick Ratio | 0.43 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 3.61 |
| Debt / FCF | -154.20 |
| Interest Coverage | 1.36 |
Financial Efficiency
Return on equity (ROE) is 0.58% and return on invested capital (ROIC) is 2.95%.
| Return on Equity (ROE) | 0.58% |
| Return on Assets (ROA) | 2.46% |
| Return on Capital (ROIC) | 2.95% |
| Revenue Per Employee | 12.95M |
| Profits Per Employee | 67,465 |
| Employee Count | 6,719 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 1.54 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +109.03% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +109.03% |
| 50-Day Moving Average | 239.84 |
| 200-Day Moving Average | 174.21 |
| Relative Strength Index (RSI) | 47.99 |
| Average Volume (20 Days) | 19,870,480 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Piramal Pharma had revenue of INR 87.04 billion and earned 453.30 million in profits. Earnings per share was 0.34.
| Revenue | 87.04B |
| Gross Profit | 52.36B |
| Operating Income | 5.90B |
| Pretax Income | 3.22B |
| Net Income | 453.30M |
| EBITDA | 12.87B |
| EBIT | 5.90B |
| Earnings Per Share (EPS) | 0.34 |
Balance Sheet
The company has 4.08 billion in cash and 47.86 billion in debt, giving a net cash position of -43.78 billion or -33.02 per share.
| Cash & Cash Equivalents | 4.08B |
| Total Debt | 47.86B |
| Net Cash | -43.78B |
| Net Cash Per Share | -33.02 |
| Equity (Book Value) | 79.07B |
| Book Value Per Share | 59.51 |
| Working Capital | 1.44B |
Cash Flow
In the last 12 months, operating cash flow was 6.81 billion and capital expenditures -7.12 billion, giving a free cash flow of -310.40 million.
| Operating Cash Flow | 6.81B |
| Capital Expenditures | -7.12B |
| Free Cash Flow | -310.40M |
| FCF Per Share | -0.23 |
Margins
Gross margin is 60.15%, with operating and profit margins of 6.77% and 0.52%.
| Gross Margin | 60.15% |
| Operating Margin | 6.77% |
| Pretax Margin | 3.70% |
| Profit Margin | 0.52% |
| EBITDA Margin | 14.79% |
| EBIT Margin | 6.77% |
| FCF Margin | -0.36% |
Dividends & Yields
This stock pays an annual dividend of 0.11, which amounts to a dividend yield of 0.04%.
| Dividend Per Share | 0.11 |
| Dividend Yield | 0.04% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.21% |
| Shareholder Yield | -9.16% |
| Earnings Yield | 0.14% |
| FCF Yield | -0.10% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |